Plethora Solutions PLC
Plethora Solutions (AIM: PLE) is a speciality pharmaceutical company dedicated to the development and marketing of products for the treatment and management of urological disorders.
The diagnosis and treatment of urological conditions represents an expanding market with many poorly met medical needs that offer significant commercial potential for new pharmaceutical products and medical devices.
The Company's principal product is referred to under its development name of PSD 502, a treatment remedy for male premature ejaculation.
Introducing PSD502 - The answer to PE
More than 25 million men across Europe alone suffer from premature ejaculation (PE), for which there is no known cure. As well as the physical and sexual issues associated with PE, it can also cause extreme emotional distress.
Following the regulatory approval by European Medicines Agency (EMA) in November 2013, PSD502 is the first clinically effective, fast-acting treatment for PE, offering hope for millions of men - and their partners.
Benefits of PSD502
- Fast-acting - used 5 minutes before intercourse
- Effective from 1st dose
- No partner transfer
- No material side-effects